AbbVie is in a sustained uptrend, with a 1-year price change of +27.22% and the stock currently trading at 94.8% of its 52-week range ($184.63–$261.64). The price near the 52-week high suggests strong bullish momentum, though it also raises caution about potential overextension. The stock has outperformed the S&P 500 over the past year (SPY +20.63%), indicating relative strength. Short-term momentum is accelerating: the 1-month change is +10.28% and the 3-month change is +19.30%, both outpacing the S&P 500's 1-month and 3-month gains of 4.07% and 11.11%, respectively. This acceleration aligns with the longer-term uptrend, confirming strong buying pressure. The RSI is not provided, but the rapid price increase from ~$205 in late April to $248 on July 10 suggests it may be approaching overbought territory. Key support lies near the 52-week low of $184.63, while resistance is at the 52-week high of $261.64. A breakout above $261.64 would signal a continuation of the uptrend, while a breakdown below $184.63 would indicate a reversal. Beta is 0.283, meaning the stock is significantly less volatile than the market—a 1% move in SPY corresponds to a 0.283% move in ABBV. This low beta makes AbbVie a defensive holding, but it also means the stock may lag during strong market rallies.

Revenue is growing, with Q4 2025 revenue of $16.618 billion, up 10.04% year-over-year. The growth trajectory is accelerating: Q1 2025 revenue was $13.343 billion, Q2 $15.423 billion, Q3 $15.776 billion, and Q4 $16.618 billion, showing sequential acceleration. Key growth drivers are Skyrizi ($5.006B in Q4) and Rinvoq ($2.374B), which are offsetting Humira's decline ($1.246B). The aesthetics segment (Botox Cosmetic $717M, Juvederm $249M) and neuroscience (Vraylar $1.022B, Botox Therapeutic $990M) also contribute. The revenue growth supports the investment case that AbbVie is successfully navigating the Humira patent cliff. Profitability is solid but uneven: net income in Q4 2025 was $1.816 billion (net margin 10.93%), while gross margin was 84.02%. However, net income has been volatile—Q3 2025 net income was only $186 million (net margin 1.18%) due to higher expenses, while Q2 2025 net income was $938 million (6.08% margin). The operating margin in Q4 was 34.96%, indicating strong core profitability. The company is profitable overall, with trailing twelve-month net income of $4.166 billion. Margins are generally healthy but can fluctuate due to acquisition costs and R&D spending. The balance sheet shows high leverage: debt-to-equity is -21.12 (negative equity due to accumulated deficits), and the current ratio is 0.67, indicating potential liquidity risk. However, free cash flow is robust—TTM FCF is $18.701 billion, and Q4 2025 FCF was $4.889 billion. The company generates ample cash to cover dividends ($2.911B paid in Q4) and debt service. ROE is negative (-129.24%) due to negative equity, but ROA is 10.03%, reflecting efficient asset use. The high debt load is manageable given strong cash flows, but investors should monitor leverage.